Roche dou­bles down on high-im­pact projects af­ter slash­ing 20% of its pipeline

Roche has axed one-fifth of its pipeline since the third quar­ter of 2023 as part of a broad­er port­fo­lio re­view aimed at boost­ing the com­pa­ny’s fo­cus on high-im­pact projects.

“We’ve tak­en out 20% of our mol­e­cules that have a low­er like­li­hood to suc­ceed, and we’ve added new ones through part­ner­ing,” CEO Thomas Schi­neck­er said on a first-quar­ter earn­ings call with the me­dia. It’s part of nor­mal busi­ness to pri­or­i­tize and “con­stant­ly re­al­lo­cate,” he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER